~~<i id='3F7AEEE38F'><strike id='3F7AEEE38F'><tt id='3F7AEEE38F'><pre id='3F7AEEE38F'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

knowledge

author：Wikipedia 2025-09-27 15:20:48 - browse：49

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： The science behind Janet Jackson's pregnancy at 49

focus

knowledge

hotspot

explore

3:01NationalParkServiceRangersGiaPonce(L)andChristinaCaparelliarephotographedbyRangerNicoleBernardne

WSS

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

UK homeowners get some respite as inflation falls by more than anticipated to a 15

#NeedHerScience: shining a light on gender disparities in medicine

In areas with more Black doctors, Black people live longer

3 hurdles to bringing medical devices to the U.S. market

explore

knowledge

focus

How to save PrEP access — and even expand it

The strategy behind pharma's lawsuits over drug pricing reform

Medical records are filled with copy

Robert Kennedy Jr.'s presidential campaign attracts GOP

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Paxlovid study fails to answer questions over benefit for broader groups

Hollywood unions extend contract negotiations for actors

House passes resolution saying Israel isn't a 'racist or apartheid state'

Duchenne breakthrough therapy leaves behind pioneering families

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

knowledge

ER docs worry over extreme heat as a 'mass casualty event'

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Disclosing genetic information: not as worrisome as once feared

STAT's guide to the next generation of CAR

With FDA staff opposed to Sarepta therapy, top official intervened

knowledge

hotspot

hotspot

explore